229 related articles for article (PubMed ID: 30531832)
21. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
[TBL] [Abstract][Full Text] [Related]
22. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
[TBL] [Abstract][Full Text] [Related]
23. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Shitara K; Yonesaka K; Denda T; Yamazaki K; Moriwaki T; Tsuda M; Takano T; Okuda H; Nishina T; Sakai K; Nishio K; Tokunaga S; Yamanaka T; Boku N; Hyodo I; Muro K
Cancer Sci; 2016 Dec; 107(12):1843-1850. PubMed ID: 27712015
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
25. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
26. MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.
Parikh AR; Lee FC; Yau L; Koh H; Knost J; Mitchell EP; Bosanac I; Choong N; Scappaticci F; Mancao C; Lenz HJ
Clin Cancer Res; 2019 May; 25(10):2988-2995. PubMed ID: 30224341
[TBL] [Abstract][Full Text] [Related]
27. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
28. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis.
Chen K; Gong Y; Zhang Q; Shen Y; Zhou T
Medicine (Baltimore); 2016 Nov; 95(46):e5221. PubMed ID: 27861344
[TBL] [Abstract][Full Text] [Related]
30. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).
Suenaga M; Nishina T; Mizunuma N; Yasui H; Ura T; Denda T; Ikeda J; Esaki T; Nishisaki H; Takano Y; Sugiyama Y; Muro K
BMC Cancer; 2015 Mar; 15():176. PubMed ID: 25884814
[TBL] [Abstract][Full Text] [Related]
31. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
[TBL] [Abstract][Full Text] [Related]
32. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Souglakos J; Ziras N; Kakolyris S; Boukovinas I; Kentepozidis N; Makrantonakis P; Xynogalos S; Christophyllakis Ch; Kouroussis Ch; Vamvakas L; Georgoulias V; Polyzos A
Br J Cancer; 2012 Jan; 106(3):453-9. PubMed ID: 22240792
[TBL] [Abstract][Full Text] [Related]
33. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Michl M; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmueller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Mueller S; Lerch MM; Modest DP; Kirchner T; Jung A; Heinemann V;
Ann Oncol; 2016 Aug; 27(8):1565-72. PubMed ID: 27234640
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
36. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.
Deng T; Zhang L; Liu XJ; Xu JM; Bai YX; Wang Y; Han Y; Li YH; Ba Y
Med Oncol; 2013 Dec; 30(4):752. PubMed ID: 24174316
[TBL] [Abstract][Full Text] [Related]
38. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
40. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Toffoli G; Sharma MR; Marangon E; Posocco B; Gray E; Mai Q; Buonadonna A; Polite BN; Miolo G; Tabaro G; Innocenti F
Clin Cancer Res; 2017 Feb; 23(4):918-924. PubMed ID: 27507617
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
